Nutrition Support for Cancer Patients throughout the Continuum of Care

2021 ◽  
pp. 271-323
Author(s):  
Refaat Hegazi ◽  
Katie N. Robinson ◽  
Bridget A. Cassady ◽  
Sara Thomas ◽  
Mohamed El-Gamal ◽  
...  
Author(s):  
Partha Basu ◽  
Richa Tripathi ◽  
Ravi Mehrotra ◽  
Koninika Ray ◽  
Anurag Srivastava ◽  
...  

2020 ◽  
Vol 16 (2) ◽  
pp. 4337-4339 ◽  
Author(s):  
Marco Puzzoni ◽  
Pina Ziranu ◽  
Laura Demurtas ◽  
Eleonora Lai ◽  
Stefano Mariani ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17510-e17510
Author(s):  
A. Amin ◽  
J. Lin ◽  
A. Ryan

e17510 Background: The period of VTE risk in cancer patients extends beyond the hospital stay. This analysis evaluated VTE prophylaxis patterns for US cancer patients across the continuum of care. Methods: Premier's Perspective inpatient data were cross-matched with Ingenix LabRx outpatient data from the I3 database (January 2005-December 2007) to assess VTE prophylaxis patterns in medical cancer patients at risk of VTE (according to the American College of Chest Physicians 2004 guidelines) and with no contraindications for anticoagulation. Inpatient anticoagulant groups were assigned based on the drug the patient received during hospital stay and were followed by their outpatient prophylaxis use. Patients were evaluated on drug utilization, diagnoses and clinical practice patterns during and after hospitalization. Results: Overall, 75.3% of 2,337 cancer patients did not receive anticoagulation during their hospital stay. Of the 577 patients receiving prophylaxis, 66% received UFH and 25% received enoxaparin ( Table ). The mean length of hospital stay was 3 days after which 97.9% of patients did not receive any prophylaxis within the following 30 days. Of the 50 patients who received outpatient prophylaxis, 60% received warfarin alone and 22% received both enoxaparin and warfarin. Conclusions: This unique analysis presents VTE prophylaxis patterns across the continuum of care. Most cancer patients did not receive anticoagulation in the inpatient or outpatient settings. Further efforts are needed to identify optimal VTE prevention in cancer patients, namely the duration of prophylaxis and how healthcare providers can increase awareness. Financial and editorial support was provided by sanofi-aventis US, Inc. [Table: see text] [Table: see text]


Author(s):  
Maitane GARCÍA-LÓPEZ ◽  
Ester VAL ◽  
Ion IRIARTE ◽  
Raquel OLARTE

Taking patient experience as a basis, this paper introduces a theoretical framework, to capture insights leading to new technological healthcare solutions. Targeting a recently diagnosed type 1 diabetes child and her mother (the principal caregiver), the framework showed its potential with effective identification of meaningful insights in a generative session. The framework is based on the patient experience across the continuum of care. It identifies insights from the patient perspective: capturing patients´ emotional and cognitive responses, understanding agents involved in patient experience, uncovering pain moments, identifying their root causes, and/or prioritizing actions for improvement. The framework deepens understanding of the patient experience by providing an integrated and multi-leveled structure to assist designers to (a) empathise with the patient and the caregiver throughout the continuum of care, (b) understand the interdependencies around the patient and different agents and (c) reveal insights at the interaction level.


1992 ◽  
Vol 14 (3) ◽  
pp. 376-398 ◽  
Author(s):  
Baila Miller ◽  
Stephanie McFall

Sign in / Sign up

Export Citation Format

Share Document